Jeffrey S. Ramsay

Davis Polk advised the joint book-running managers in connection with the $172 million public offering of common stock of Deciphera Pharmaceuticals, Inc. The common stock is listed on…

Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to which its indirect wholly owned subsidiary, Valeant Pharmaceuticals…

Davis Polk advised the Province of New Brunswick in connection with the offering of $500 million aggregate principal amount of 3.625% bonds due February 24, 2028. The Davis Polk team…

Davis Polk advised the underwriter in connection with the $56.6 million secondary offering of 2,200,000 shares of common stock of TriState Capital Holdings, Inc. by selling…

Davis Polk advised MSCI Inc. in connection with a Rule 144A/Regulation S offering of $500 million aggregate principal amount of its 5.375% senior notes due 2027 and a concurrent amendment…

Davis Polk advised the joint book-running managers on a Rule 144A/Regulation S offering by TopBuild Escrow Corp., a wholly owned subsidiary of TopBuild Corp., of $400 million aggregate…

Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 5.500% senior notes…

Davis Polk advised the representatives of the several underwriters in connection with the registered offering of £250 million aggregate principal amount of 2.750% senior notes due 2025. DXC…

Davis Polk advised the underwriters in connection with the offering of $1 billion aggregate principal amount of 2.750% U.S. dollar bonds due 2023 issued by Export Development Canada…

Davis Polk advised the underwriters in connection with the SEC-registered offering of $1.25 billion aggregate principal amount of 3.300% bonds due March 15, 2028, issued by the Province of…